701977-09-5

Basic information

• Product Name: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)
• Synonyms: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364);MK 0364;N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide;Taranabant;Tranabant;N-(3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide;Propanamide, N-((1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)-2-pyridinyl)oxy)-;Taranabant [usan]
• CAS NO: 701977-09-5
• Molecular Formula: C₂₇H₂₅ClF₃N₃O₂
• Molecular Weight: 515.95
• Mol File: 701977-09-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 106.0-106.3 °C
• Boiling Point: 634.2 °C at 760 mmHg
• Flash Point: 337.4 °C
• Appearance: /
• Density: 1.30
• PKA: 14.55±0.46(Predicted)
• CAS DataBase Reference: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(701977-09-5)
• EPA Substance Registry System: N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)(701977-09-5)

Safety Data

• Hazardous Substances Data: 701977-09-5(Hazardous Substances Data)

Usage

General Description

MK 0364 is a chemical compound with the molecular formula C28H24ClF3N4O2. It is also known as N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide. MK 0364 is a potent and selective potassium channel opener, and it has shown potential for the treatment of various conditions, including epilepsy and neuropathic pain. It works by modulating the activity of certain potassium channels in the brain and nervous system, which can help to reduce abnormal electrical activity and alleviate symptoms associated with these conditions. Additionally, MK 0364 has been studied for its potential use in treating anxiety and depression. Its complex chemical structure and specific mode of action make it a promising candidate for further research and development in the field of neuroscience and drug discovery.

InChI:InChI=1/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)

Upstream product

• 605680-62-4 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoic acid 
• 610791-48-5 N-[3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]amine hydrochloride 
• 848310-98-5 3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-one 
• 913849-17-9 ethyl 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoate 
• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 
• 622-95-7 4-chlorobenzyl bromide 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 876365-70-7 N-[(1Z)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylprop-1-en-1-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 

Relevant articles and documents

LIQUID PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF A SUBSTITUTED AMIDE

A liquid pharmaceutical composition comprising N-[1S,2S]-3-[(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[(5-trifluoromethyl)pyridine-2-yl]oxy}propanamide is disclosed, together with processes of preparing the liquid pharmaceutical compo

Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

Chiral amide 1 (MK-0364, taranabant) is a potent, selective, and orally bioavailable cannabinoid-1 receptor (CB-1R) inverse agonist indicated for the treatment of obesity. An asymmetric synthesis featuring a dynamic kinetic resolution via hydrogenation fo

Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.